PTC India's net profit in the second quarter fell by over 28% to 159 crore rupees due to rising expenses
Read more
Business Standard
business-standard.com

PTC India's net profit in the second quarter fell by over 28% to 159 crore rupees due to rising expenses

PTC India reported a decline in consolidated net profit of over 28% in the September quarter, reaching 159.10 crore rupees. The main reason for this decrease was increased expenses.

The company noted that in the second quarter of the previous fiscal year, net profit amounted to 222.05 crore rupees. Despite this profit decline, the company's total revenue in the second quarter of fiscal year 27 increased to 5,958.24 crore rupees compared to 5,585.21 crore rupees the previous year.

Meanwhile, total expenses rose to 5,788.97 crore rupees during the period from July to September of fiscal year 26, an increase compared to 5,287.25 crore rupees.

Dynamics and Growth Factors

In its statement, PTC India indicated that the volume of individual trades grew by 24 percent, reaching 32.46 billion units (BUs) in the second quarter of fiscal year 27. Manoj Kumar Jawar, CEO of PTC India Ltd, stated that the growth in the second quarter was driven by transactions conducted across various timeframes.

He also noted that a significant decrease in cross-border electricity from Bhutan occurred due to increased domestic demand in Bhutan, which led to a corresponding reduction in trading revenue.

Similar stories

Sun Pharma's net profit fell by 36% in the second quarter due to one-time expenses, despite a 12% revenue increase
Read more
business-standard.com

Sun Pharma's net profit fell by 36% in the second quarter due to one-time expenses, despite a 12% revenue increase

Sun Pharmaceutical Industries, India's largest drug manufacturer, reported on Friday a 36% year-on-year decline in consolidated net profit, reaching ₹1,988.5 crore in the second quarter of the fiscal year 2026-27 (FY27). This decrease was attributed to significant exceptional expenses.

Meanwhile, operating revenue increased by 11.9%, amounting to ₹16,198.7 crore. The company accounted for exceptional expenses totaling ₹1,268.8 crore. These expenses include ₹922.7 crore spent on settling an antitrust lawsuit in the United States (US), as well as ₹346.2 crore for costs related to the proposed acquisition of Organon.

Excluding these exceptional items, the adjusted net profit stood at ₹3,162 crore, demonstrating a growth of 1.4% compared to the same period last year. The company noted that the margin was lower than the previous year because the previous quarter saw a rise in sales of the generic lenalidomide, which is now facing weakening in the US market.

The gross margin improved to 80.8%, and the effective tax rate rose from 24.7% to 28.3%. The results were announced during the trading session, after which Sun Pharma shares rose by 0.8% and closed at ₹1,778.25 on the BSE exchange.

Kirti Ganorkar, Managing Director, stated that the company's success in the reporting quarter was driven by strong momentum from India, emerging markets, and the rest of the world. Prescription drug sales in India grew by 17.3%, reaching ₹5,552.3 crore, accounting for 34.5% of total sales. According to Pharmarack's MAT data, Sun Pharma's market share increased from 8.3% to 8.6%.

During the quarter, the company launched 14 new products, and 19 in the first half of FY27. Prescription drug sales in the US decreased by 8.2% to $455 million, making up about 27% of the total volume. Research and Development (R&D) expenses for the quarter amounted to ₹778.4 crore, or 4.8% of sales. Dilip Shanghvi, Chairman, noted that these figures are below planned R&D expenditures but expects to reach some level of target R&D spending in the second half of the year.

KPIT Technologies' profit decreased by 29% in the second quarter of fiscal year 27
Read more
business-standard.com

KPIT Technologies' profit decreased by 29% in the second quarter of fiscal year 27

KPIT Technologies reported a nearly 29% drop in consolidated net profit, amounting to 121 crore rupees, for the second quarter ending in September. The main reason for this decline was pressure on the automotive market from Chinese manufacturers, which slowed down deal closures.

In the same period last year, the company demonstrated a net profit of 169 crore rupees. KPIT management expects losses to begin decreasing starting from the third quarter.

Forecasts and Market Trends

Sachin Tikekar, Co-founder and Joint Managing Director of KPIT Technologies, noted that a significant profit decline was observed among two of the company's largest clients—one in Europe and another in Japan. He expressed confidence that these contracts will hit a bottom within the next few quarters, possibly two or three. Nevertheless, he forecasts gradual growth among existing OEM clients in the passenger car, truck, and SUV segments.

In the reporting quarter, KPIT Technologies' consolidated revenue from operations increased by 6.5% to 1,691 crore rupees, compared to 1,588 crore rupees the previous year. However, revenue from the passenger car segment fell by 7.8% year-on-year to USD 132.36 million (approximately 1,260 crore rupees). Meanwhile, commercial vehicle segment revenue grew by 27.3% to USD 39.98 million (nearly 375 crore rupees).

Tikekar stated that the company's prospects look more encouraging. He highlighted nervousness among European passenger car manufacturers, which is leading to a slowdown in the decision-making process. Although the company is winning many new orders, the pace of decision-making remains slightly slow; however, in his opinion, the situation is moving in the right direction, confirming the effectiveness of the adopted strategy.

He also pointed to the immense pressure being exerted on European passenger car manufacturers regarding sales, which continue to decline, as well as on their margins. According to him, companies are forced to implement cost-cutting initiatives, which will likely continue for several more quarters. This pressure is driven by competition they face in China, as well as competition from China in other regions, including Europe, Southeast Asia, the Middle East, and others.

The total contract value secured by the company in the reporting quarter amounted to USD 213 million (about 2,026 crore rupees). Tikekar added that American OEMs are in a relatively protected position because most of their revenue comes from America. He noted that Japanese manufacturers are also in a better position, as America and Japan are two of their largest markets. Although there is some decline in indicators for Japanese, Korean, and American companies, it is minor compared to what European OEMs are experiencing.

In contrast, the situation in India for passenger cars is drastically different, as this market is the fastest growing. Tikekar noted that both local Indian OEMs and some foreign players are gaining momentum. Growth is observed particularly in Maruti Suzuki, Mahindra, Tata Motors, Hyundai, and Kia, while the position of Chinese and Vietnamese companies is noticeably strengthening in the electric vehicle segment.

Cipla's net profit in the second quarter fell by 35% to 877.5 billion rupees
Read more
business-standard.com

Cipla's net profit in the second quarter fell by 35% to 877.5 billion rupees

Pharmaceutical giant Cipla reported on Tuesday a 35% decrease in consolidated net profit for the second quarter, which ended in September. Meanwhile, revenue showed a slight decline, and expenses increased during the reporting period.

According to regulatory filings, in the same period last year, the company earned a net profit of 1351.17 billion rupees. For the quarter from July to September, total operating income decreased to 7403.93 billion rupees compared to 7589.44 billion rupees the previous year.

Concurrently, total expenses rose to 6377.75 billion rupees, whereas they were 6004.86 billion rupees in the second quarter of the previous fiscal year.

Popular